Survivin and COX-2 expression in male breast carcinoma

Breast

Volumn 18, Issue 4, 2009, Pages 228-232

  Younis, Tallal ^a   Haché, Kelly Dakin ^a   Rayson, Daniel ^a   Dewar, Ron ^b   Gray, Samantha ^a   Barnes, Penny J ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b Surveillance and Epidemiology Unit   (Canada)

Author keywords

Aromatase; COX 2; Male breast cancer; Prognostic markers; Survivin; Tissue microarray

Indexed keywords

CYCLOOXYGENASE 2; SURVIVIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANADA; CANCER GRADING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA, MUCINOUS; AROMATASE; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ARRAY ANALYSIS;

EID: 69949091960     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.06.003     Document Type: Article

References (32)

1. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344 4 (2001) 276-285
2. Sasco A.J., Kaaks R., and Little R.E. Breast cancer: occurrence, risk factors and hormone metabolism. Expert Rev Anticancer Ther 3 4 (2003) 546-562
3. Giordano S.H. A review of the diagnosis and management of male breast cancer. Oncologist 10 7 (2005) 471-479
4. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
5. Dakin Haché K., Gray S., Barnes P.J., Dewar R., Younis T., and Rayson D. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 105 2 (2007) 169-175
6. Li F., and Brattain M.G. Role of the Survivin gene in pathophysiology. Am J Pathol 169 1 (2006) 1-11
7. Li F., and Ling X. Survivin study: an update of "what is the next wave"?. J Cell Physiol 208 3 (2006) 476-486
8. Li F., Yang J., Ramnath N., Javle M.M., and Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer 114 4 (2005) 509-512
9. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6 (2000) 127-134
10. Kennedy S.M., O'Driscoll L., Purcell R., Fitz-Simons N., McDermott E.W., Hill A.D., et al. Prognostic importance of survivin in breast cancer. Br J Cancer 88 7 (2003) 1077-1083
11. Kayaselcuk F., Nursal T.Z., Polat A., Noyan T., Yildirim S., Tarim A., et al. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res 23 1 (2004) 105-112
12. Chu J.S., Shew J.Y., and Huang C.S. Immunohistochemical analysis of survivin expression in primary breast cancers. J Formos Med Assoc 103 12 (2004) 925-931
13. Son B.H., Choi J.S., and Lee J.H. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology 37 2 (2005) 131-136
14. Singh M., Bleile M.J., Shroyer A.L., Heinz D., Jarboe E.A., and Shroyer K.R. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl Immunohistochem Mol Morphol 12 4 (2004) 296-304
15. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
16. Howe L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9 4 (2007) 210
17. Ristimäki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62 (2002) 632-635
18. Subbaramaiah K., Norton L., Gerald W., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 277 (2002) 18649-18657
19. Boland G.P., Butt I.S., Prasad R., Knox W.F., and Bundred N.J. COX-2 expression is associated with an aggressive henotype in ductal carcinoma in situ. Br J Cancer 90 (2004) 423-429
20. Krysan K., Dalwadi H., Sharma S., Põld M., and Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64 (2004) 6359-6362
21. Barnes N., Haywood P., Flint P., Knox W.F., and Bundred N.J. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 94 2 (2006) 253-258
22. Brueggemeier R.W., Quinn A.L., Parrett M.L., Joarder F.S., Harris R.E., and Robertson F.M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140 (1999) 27-35
23. Brodie A.M., Lu Q., Long B.J., Fulton A., Chen T., Macpherson N., et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79 (2001) 41-47
24. Diaz-Cruz E.S., Shapiro C.L., and Brueggemeier R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90 (2005) 2563-2570
25. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 5 (1991) 403-410
26. Brennan D.J., Rexhepaj E., O'Brien S.L., McSherry E., O'Connor D.P., Fagan A., et al. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res. 14 9 (2008) 2681-2689
27. Arun B., and Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31 2 Suppl. 7 (2004) 22-29
28. Agrawal A., and Fentiman I.S. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62 3 (2008) 444-449
29. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92 2 (2005) 212-216
30. Ryan B., O'Donovan N., Browne B., O'Shea C., Crown J., Hill A.D., et al. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92 1 (2005) 120-124
31. Vegran F., Boidot R., Oudin C., Riedinger J.M., and Lizard-Nacol S. Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol 27 4 (2005) 1151-1157
32. Ryan B.M., Konecny G.E., Kahlert S., Wang H.J., Untch M., Meng G., et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17 4 (2006) 597-604